<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02111785</url>
  </required_header>
  <id_info>
    <org_study_id>17294</org_study_id>
    <nct_id>NCT02111785</nct_id>
  </id_info>
  <brief_title>Dexamethasone Versus Burr Hole Craniostomy for Symptomatic Chronic Subdural Hematoma</brief_title>
  <acronym>DECS</acronym>
  <official_title>The DECS Trial: DExamethasone Versus Burr Hole Craniostomy for Symptomatic Chronic Subdural Hematoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic subdural hematoma (cSDH) is condition where blood has slowly leaked out of small
      blood vessels surrounding the brain. Over time, the blood may cause a variety of symptoms
      including headache, confusion, limb weakness, and difficulty speaking.

      There is currently no agreement among physicians as to the best way to treat this condition.

      The study hypothesis to be tested was: For patients with unilateral, symptomatic chronic
      subdural hematoma, there is no difference in clinical outcomes, as measured by achievement of
      modified Rankin Score of 0-2 at 6 months, between those treated with a 2 week course of oral
      dexamethasone, compared with those treated with burr hole surgical drainage.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic subdural hematoma (cSDH) is condition where blood has slowly leaked out of small
      blood vessels surrounding the brain. Over time, the blood may cause a variety of symptoms
      including headache, confusion, limb weakness, and difficulty speaking.

      There is currently no agreement among physicians as to the best way to treat this condition.
      One option is to do a surgery to drain the blood that has collected. Usually the surgery
      involves drilling small holes in the skull to relieve pressure and allow blood and fluids to
      be drained. Another option is to give medications such as steroids that might reduce the
      swelling. However, no drugs have been approved by the Food and Drug Administration (FDA)
      specifically to treat this condition. Some patients elect to have no treatment.

      The purpose of this study was to investigate whether investigational treatment with a 2 week
      course of oral dexamethasone is as effective as surgery for cSDH. The study hypothesis to be
      tested was: For patients with unilateral, symptomatic chronic subdural hematoma, there is no
      difference in clinical outcomes, as measured by achievement of modified Rankin Score of 0-2
      at 6 months, between those treated with a 2 week course of oral dexamethasone, compared with
      those treated with burr hole surgical drainage.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Accrual too slow; Study P.I. passed away.
  </why_stopped>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With a Modified Rankin Score of 0, 1 or 2</measure>
    <time_frame>6 months after diagnosis</time_frame>
    <description>The Modified Rankin Scale (mRS)
The mRS is evaluated as follows:
0 - No symptoms
- No significant disability. Able to carry out all usual activities, despite some symptoms.
- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.
- Moderate disability. Requires some help, but able to walk unassisted.
- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.
- Severe disability. Requires constant nursing care and attention, bedridden, incontinent.
- Dead.
Higher scores on the mRS scale mean a worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Treatment Failure</measure>
    <time_frame>6 months after diagnosis</time_frame>
    <description>This measure includes rate of repeat surgery in the burr hole group and rate of progression to surgery in the dexamethasone group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Modified Rankin Score 0, 1 or 2 at 6 Months</measure>
    <time_frame>6 months after hospital discharge</time_frame>
    <description>The Modified Rankin Scale (mRS)
The mRS is evaluated as follows:
0 - No symptoms
- No significant disability. Able to carry out all usual activities, despite some symptoms.
- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.
- Moderate disability. Requires some help, but able to walk unassisted.
- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.
- Severe disability. Requires constant nursing care and attention, bedridden, incontinent.
- Dead.
Higher scores on the mRS scale mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With a Glasgow Coma Scale Score of 15 at 6 Month Follow-up</measure>
    <time_frame>6 months after hospital discharge</time_frame>
    <description>Glasgow Coma Scale (GCS) The GCS is evaluated on a scale from 3 to 15, with higher scores indicating better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With a Markwalder Grading Score of 0</measure>
    <time_frame>6 months after hospital discharge</time_frame>
    <description>Markwalder Grading Score (MGS)
The MGS is assessed as follows:
Grade 0 - Patient neurologically normal Grade 1 - Patient alert and oriented; mild symptoms, such as headache; absent or mild symptoms or neurologic deficit, such as reflex asymmetry Grade 2 - Patient drowsy or disoriented with variable neurological deficit, such as hemiparesis Grade 3 - Patient stuporous but responding appropriately to noxious stimuli; several focal signs, such as hemiparesis Grade 4 - Patient comatose with absent motor response to painful stimuli; decerebrate or decorticate posturing.
Higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Rate of Radiographic Resolution of Chronic Subdural Hematoma</measure>
    <time_frame>6 months after diagnosis</time_frame>
    <description>The data were not collected.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Chronic Subdural Hematoma</condition>
  <arm_group>
    <arm_group_label>Burr Hole Craniostomy randomized</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group receiving burr hole craniostomy and drainage of chronic subdural hematoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexamethasone randomized</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexamethasone, tablet, initial dose 4mg q8h, total duration 15 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Burr hole craniostomy observational</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Observational cohort of patients selecting burr hole craniostomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexamethasone observational</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Observational cohort of patients treated with dexamethasone protocol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Treatment with a short course of oral dexamethasone</description>
    <arm_group_label>Dexamethasone observational</arm_group_label>
    <arm_group_label>Dexamethasone randomized</arm_group_label>
    <other_name>dex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Burr Hole Craniostomy</intervention_name>
    <description>Treatment with surgical burr hole craniostomy and evacuation of SDH</description>
    <arm_group_label>Burr Hole Craniostomy randomized</arm_group_label>
    <arm_group_label>Burr hole craniostomy observational</arm_group_label>
    <other_name>Burr hole drainage</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subject aged 18 years of age or older

          -  Informed consent obtained from a patient or a legal representative before enrollment

          -  Enrollment into the study within 12 hours of detection of chronic subdural hematoma on
             cranial imaging

          -  Presence of symptoms referable to chronic subdural hematoma, including one or more of
             the following: Headache; altered mental status, limb weakness, dysphasia, or focal
             neurological deficit

          -  Demonstration of unilateral chronic subdural hematoma on cranial imaging, including
             the following features: On computed tomography imaging, iso- or hypo-intensity
             extra-axial collection with or without presence of acute component; radiologic
             interpretation of magnetic resonance imaging consistent with subacute or chronic SDH;
             with or without evidence of acute hemorrhagic component

          -  Maximum depth of subdural hematoma of less than 20mm, with less than 10mm of midline
             shift, as measured on axial CT or MR imaging

          -  Absence of skull fracture over the subdural hematoma

          -  Able to receive the drug treatment

        Exclusion Criteria:

          -  Presence of skull fracture over the subdural hematoma, or other specific etiology for
             cSDH not suitable for drainage by burr hole craniostomy, such as presence of a
             ventriculoperitoneal shunt

          -  Extent of subdural hematoma &gt; 20mm in maximal depth, or &gt; 10mm of midline shift, as
             measured on axial CT or MR imaging

          -  GCS &lt;8 or cSDH of an extent or size for which craniotomy, rather than burr hole
             drainage alone, is judged necessary by the neurosurgery attending on call

          -  Prior diagnosis of dementia

          -  Presence of symptomatic peptic ulcer, psychosis, active or suspected TB, acute
             infection, or documented hypersensitivity or allergy to dexamethasone

          -  Pregnancy (confirmed by a serum human chorionic gonadotropin pregnancy test) or breast
             feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer De Jong</last_name>
    <role>Study Director</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>April 3, 2014</study_first_submitted>
  <study_first_submitted_qc>April 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2014</study_first_posted>
  <results_first_submitted>August 20, 2018</results_first_submitted>
  <results_first_submitted_qc>November 19, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 11, 2018</results_first_posted>
  <last_update_submitted>November 19, 2018</last_update_submitted>
  <last_update_submitted_qc>November 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dexamethasone</keyword>
  <keyword>Burr hole craniostomy</keyword>
  <keyword>Chronic subdural hematoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematoma, Subdural</mesh_term>
    <mesh_term>Hematoma, Subdural, Chronic</mesh_term>
    <mesh_term>Hematoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 20, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/85/NCT02111785/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Burr Hole Craniostomy Randomized</title>
          <description>Group receiving burr hole craniostomy and drainage of chronic subdural hematoma
Burr Hole Craniostomy</description>
        </group>
        <group group_id="P2">
          <title>Dexamethasone Randomized</title>
          <description>Dexamethasone, tablet, initial dose 4mg q8h, total duration 15 days
Dexamethasone</description>
        </group>
        <group group_id="P3">
          <title>Burr Hole Craniostomy Observational</title>
          <description>Observational cohort of patients selecting burr hole craniostomy
Burr Hole Craniostomy</description>
        </group>
        <group group_id="P4">
          <title>Dexamethasone Observational</title>
          <description>Observational cohort of patients treated with dexamethasone protocol
Dexamethasone</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Population represents patients meeting inclusion/exclusion criteria who were enrolled in the study.</population>
      <group_list>
        <group group_id="B1">
          <title>Burr Hole Craniostomy Randomized</title>
          <description>Group receiving burr hole craniostomy and drainage of chronic subdural hematoma
Burr Hole Craniostomy</description>
        </group>
        <group group_id="B2">
          <title>Dexamethasone Randomized</title>
          <description>Dexamethasone, tablet, initial dose 4mg q8h, total duration 15 days
Dexamethasone</description>
        </group>
        <group group_id="B3">
          <title>Burr Hole Craniostomy Observational</title>
          <description>Observational cohort of patients selecting burr hole craniostomy
Burr Hole Craniostomy</description>
        </group>
        <group group_id="B4">
          <title>Dexamethasone Observational</title>
          <description>Observational cohort of patients treated with dexamethasone protocol
Dexamethasone</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="1"/>
            <count group_id="B4" value="1"/>
            <count group_id="B5" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="1"/>
                    <count group_id="B4" value="1"/>
                    <count group_id="B5" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="1"/>
                    <count group_id="B4" value="1"/>
                    <count group_id="B5" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.3" lower_limit="54" upper_limit="88"/>
                    <measurement group_id="B2" value="72.6" lower_limit="47" upper_limit="87"/>
                    <measurement group_id="B3" value="76" lower_limit="76" upper_limit="76"/>
                    <measurement group_id="B4" value="74" lower_limit="74" upper_limit="74"/>
                    <measurement group_id="B5" value="73.3" lower_limit="47" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="1"/>
                    <count group_id="B4" value="1"/>
                    <count group_id="B5" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="1"/>
                    <count group_id="B4" value="1"/>
                    <count group_id="B5" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Modified Rankin Score of 0, 1 or 2</title>
        <description>The Modified Rankin Scale (mRS)
The mRS is evaluated as follows:
0 - No symptoms
- No significant disability. Able to carry out all usual activities, despite some symptoms.
- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.
- Moderate disability. Requires some help, but able to walk unassisted.
- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.
- Severe disability. Requires constant nursing care and attention, bedridden, incontinent.
- Dead.
Higher scores on the mRS scale mean a worse outcome.</description>
        <time_frame>6 months after diagnosis</time_frame>
        <population>Number of Participants with a modified Rankin Score of 0, 1 or 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Burr Hole Craniostomy Randomized</title>
            <description>Group receiving burr hole craniostomy and drainage of chronic subdural hematoma
Burr Hole Craniostomy</description>
          </group>
          <group group_id="O2">
            <title>Dexamethasone Randomized</title>
            <description>Dexamethasone, tablet, initial dose 4mg q8h, total duration 15 days
Dexamethasone</description>
          </group>
          <group group_id="O3">
            <title>Burr Hole Craniostomy Observational</title>
            <description>Observational cohort of patients selecting burr hole craniostomy
Burr Hole Craniostomy</description>
          </group>
          <group group_id="O4">
            <title>Dexamethasone Observational</title>
            <description>Observational cohort of patients treated with dexamethasone protocol
Dexamethasone</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Modified Rankin Score of 0, 1 or 2</title>
          <description>The Modified Rankin Scale (mRS)
The mRS is evaluated as follows:
0 - No symptoms
- No significant disability. Able to carry out all usual activities, despite some symptoms.
- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.
- Moderate disability. Requires some help, but able to walk unassisted.
- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.
- Severe disability. Requires constant nursing care and attention, bedridden, incontinent.
- Dead.
Higher scores on the mRS scale mean a worse outcome.</description>
          <population>Number of Participants with a modified Rankin Score of 0, 1 or 2.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Treatment Failure</title>
        <description>This measure includes rate of repeat surgery in the burr hole group and rate of progression to surgery in the dexamethasone group</description>
        <time_frame>6 months after diagnosis</time_frame>
        <population>Reflects population analyzed for treatment failure. The one patient in the dexamethasone randomized group who died was not analyzed for this secondary outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Burr Hole Craniostomy Randomized</title>
            <description>Group receiving burr hole craniostomy and drainage of chronic subdural hematoma
Burr Hole Craniostomy: Treatment with surgical burr hole craniostomy and evacuation of SDH</description>
          </group>
          <group group_id="O2">
            <title>Dexamethasone Randomized</title>
            <description>Dexamethasone, tablet, initial dose 4mg q8h, total duration 15 days
Dexamethasone: Treatment with a short course of oral dexamethasone</description>
          </group>
          <group group_id="O3">
            <title>Burr Hole Craniostomy Observational</title>
            <description>Observational cohort of patients selecting burr hole craniostomy
Burr Hole Craniostomy: Treatment with surgical burr hole craniostomy and evacuation of SDH</description>
          </group>
          <group group_id="O4">
            <title>Dexamethasone Observational</title>
            <description>Observational cohort of patients treated with dexamethasone protocol
Dexamethasone: Treatment with a short course of oral dexamethasone</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Treatment Failure</title>
          <description>This measure includes rate of repeat surgery in the burr hole group and rate of progression to surgery in the dexamethasone group</description>
          <population>Reflects population analyzed for treatment failure. The one patient in the dexamethasone randomized group who died was not analyzed for this secondary outcome.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Modified Rankin Score 0, 1 or 2 at 6 Months</title>
        <description>The Modified Rankin Scale (mRS)
The mRS is evaluated as follows:
0 - No symptoms
- No significant disability. Able to carry out all usual activities, despite some symptoms.
- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.
- Moderate disability. Requires some help, but able to walk unassisted.
- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.
- Severe disability. Requires constant nursing care and attention, bedridden, incontinent.
- Dead.
Higher scores on the mRS scale mean a worse outcome.</description>
        <time_frame>6 months after hospital discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Burr Hole Craniostomy Randomized</title>
            <description>Group receiving burr hole craniostomy and drainage of chronic subdural hematoma
Burr Hole Craniostomy</description>
          </group>
          <group group_id="O2">
            <title>Dexamethasone Randomized</title>
            <description>Dexamethasone, tablet, initial dose 4mg q8h, total duration 15 days
Dexamethasone</description>
          </group>
          <group group_id="O3">
            <title>Burr Hole Craniostomy Observational</title>
            <description>Observational cohort of patients selecting burr hole craniostomy
Burr Hole Craniostomy</description>
          </group>
          <group group_id="O4">
            <title>Dexamethasone Observational</title>
            <description>Observational cohort of patients treated with dexamethasone protocol
Dexamethasone</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Modified Rankin Score 0, 1 or 2 at 6 Months</title>
          <description>The Modified Rankin Scale (mRS)
The mRS is evaluated as follows:
0 - No symptoms
- No significant disability. Able to carry out all usual activities, despite some symptoms.
- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.
- Moderate disability. Requires some help, but able to walk unassisted.
- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.
- Severe disability. Requires constant nursing care and attention, bedridden, incontinent.
- Dead.
Higher scores on the mRS scale mean a worse outcome.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With a Glasgow Coma Scale Score of 15 at 6 Month Follow-up</title>
        <description>Glasgow Coma Scale (GCS) The GCS is evaluated on a scale from 3 to 15, with higher scores indicating better outcome.</description>
        <time_frame>6 months after hospital discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Burr Hole Craniostomy Randomized</title>
            <description>Group receiving burr hole craniostomy and drainage of chronic subdural hematoma
Burr Hole Craniostomy</description>
          </group>
          <group group_id="O2">
            <title>Dexamethasone Randomized</title>
            <description>Dexamethasone, tablet, initial dose 4mg q8h, total duration 15 days
Dexamethasone</description>
          </group>
          <group group_id="O3">
            <title>Burr Hole Craniostomy Observational</title>
            <description>Observational cohort of patients selecting burr hole craniostomy
Burr Hole Craniostomy</description>
          </group>
          <group group_id="O4">
            <title>Dexamethasone Observational</title>
            <description>Observational cohort of patients treated with dexamethasone protocol
Dexamethasone</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With a Glasgow Coma Scale Score of 15 at 6 Month Follow-up</title>
          <description>Glasgow Coma Scale (GCS) The GCS is evaluated on a scale from 3 to 15, with higher scores indicating better outcome.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With a Markwalder Grading Score of 0</title>
        <description>Markwalder Grading Score (MGS)
The MGS is assessed as follows:
Grade 0 - Patient neurologically normal Grade 1 - Patient alert and oriented; mild symptoms, such as headache; absent or mild symptoms or neurologic deficit, such as reflex asymmetry Grade 2 - Patient drowsy or disoriented with variable neurological deficit, such as hemiparesis Grade 3 - Patient stuporous but responding appropriately to noxious stimuli; several focal signs, such as hemiparesis Grade 4 - Patient comatose with absent motor response to painful stimuli; decerebrate or decorticate posturing.
Higher scores mean a worse outcome.</description>
        <time_frame>6 months after hospital discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Burr Hole Craniostomy Randomized</title>
            <description>Group receiving burr hole craniostomy and drainage of chronic subdural hematoma
Burr Hole Craniostomy</description>
          </group>
          <group group_id="O2">
            <title>Dexamethasone Randomized</title>
            <description>Dexamethasone, tablet, initial dose 4mg q8h, total duration 15 days
Dexamethasone</description>
          </group>
          <group group_id="O3">
            <title>Burr Hole Craniostomy Observational</title>
            <description>Observational cohort of patients selecting burr hole craniostomy
Burr Hole Craniostomy</description>
          </group>
          <group group_id="O4">
            <title>Dexamethasone Observational</title>
            <description>Observational cohort of patients treated with dexamethasone protocol
Dexamethasone</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With a Markwalder Grading Score of 0</title>
          <description>Markwalder Grading Score (MGS)
The MGS is assessed as follows:
Grade 0 - Patient neurologically normal Grade 1 - Patient alert and oriented; mild symptoms, such as headache; absent or mild symptoms or neurologic deficit, such as reflex asymmetry Grade 2 - Patient drowsy or disoriented with variable neurological deficit, such as hemiparesis Grade 3 - Patient stuporous but responding appropriately to noxious stimuli; several focal signs, such as hemiparesis Grade 4 - Patient comatose with absent motor response to painful stimuli; decerebrate or decorticate posturing.
Higher scores mean a worse outcome.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Rate of Radiographic Resolution of Chronic Subdural Hematoma</title>
        <description>The data were not collected.</description>
        <time_frame>6 months after diagnosis</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <desc>Adverse events assessed included number of participants experiencing infection, seizure, medication intolerance, DVT and PE.</desc>
      <group_list>
        <group group_id="E1">
          <title>Burr Hole Craniostomy Randomized</title>
          <description>Group receiving burr hole craniostomy and drainage of chronic subdural hematoma
Burr Hole Craniostomy</description>
        </group>
        <group group_id="E2">
          <title>Dexamethasone Randomized</title>
          <description>Dexamethasone, tablet, initial dose 4mg q8h, total duration 15 days
Dexamethasone</description>
        </group>
        <group group_id="E3">
          <title>Burr Hole Craniostomy Observational</title>
          <description>Observational cohort of patients selecting burr hole craniostomy
Burr Hole Craniostomy</description>
        </group>
        <group group_id="E4">
          <title>Dexamethasone Observational</title>
          <description>Observational cohort of patients treated with dexamethasone protocol
Dexamethasone</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Daniel Raper</name_or_title>
      <organization>Department of Neurosurgery, University of Virginia Health System</organization>
      <phone>4349823244</phone>
      <email>raper@virginia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

